Parkin Gene Therapy for α-Synucleinopathy: A Rat Model of Parkinson's Disease

2005 ◽  
Vol 16 (2) ◽  
pp. 262-270 ◽  
Author(s):  
Masanori Yamada ◽  
Yoshikuni Mizuno ◽  
Hideki Mochizuki
Keyword(s):  
Parkinson’S Disease ◽  
Gene Therapy ◽  
Parkinson's Disease ◽  
Rat Model ◽  
Parkin Gene

Parkin gene therapy for α-synucleinopathy: A rat model of Parkinson's disease

2006 ◽  
Vol 12 ◽  
pp. S107-S109 ◽  
Author(s):  
Hideki Mochizuki ◽  
Masanori Yamada ◽  
Yoshikuni Mizuno
Keyword(s):  
Parkinson’S Disease ◽  
Gene Therapy ◽  
Parkinson's Disease ◽  
Rat Model ◽  
Parkin Gene

Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease

2005 ◽  
Vol 134 (1) ◽  
pp. 155-161 ◽  
Author(s):  
Jie-Sheng Zheng ◽  
Ling-Ling Tang ◽  
Shu-Sen Zheng ◽  
Ren-Ya Zhan ◽  
Yong-Qing Zhou ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Gene Therapy ◽  
Parkinson's Disease ◽  
Cell Line ◽  
Glial Cell ◽  
Rat Model ◽  
Neurotrophic Factor

Long-term correction of rat model of Parkinson's disease by gene therapy

Nature ◽  
1993 ◽  
Vol 362 (6419) ◽  
pp. 450-453 ◽  
Author(s):  
Shoushu Jiao ◽  
Vladimir Gurevich ◽  
Jon A. Wolff
Keyword(s):  
Parkinson’S Disease ◽  
Gene Therapy ◽  
Parkinson's Disease ◽  
Rat Model

scholarly journals Subthalamic hGAD65 Gene Therapy and Striatum TH Gene Transfer in a Parkinson’s Disease Rat Model

2013 ◽  
Vol 2013 ◽  
pp. 1-12 ◽  
Author(s):  
Deyu Zheng ◽  
Xiaohua Jiang ◽  
Junpeng Zhao ◽  
Deyi Duan ◽  
Huanying Zhao ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Gene Therapy ◽  
Parkinson's Disease ◽  
Gene Transfer ◽  
Gene Delivery ◽  
Glutamic Acid ◽  
Rat Model ◽  
Combination Method ◽  
Combination Group ◽  
Acid Decarboxylase

The aim of the present study is to detect a combination method to utilize gene therapy for the treatment of Parkinson’s disease (PD). Here, a PD rat model is used for thein vivogene therapy of a recombinant adeno-associated virus (AAV2) containing a human glutamic acid decarboxylase 65 (rAAV2-hGAD65) gene delivered to the subthalamic nucleus (STN). This is combined with theex vivogene delivery of tyrosine hydroxylase (TH) by fibroblasts injected into the striatum. After the treatment, the rotation behavior was improved with the greatest efficacy in the combination group. The results of immunohistochemistry showed that hGAD65 gene delivery by AAV2 successfully led to phenotypic changes of neurons in STN. And the levels of glutamic acid and GABA in the internal segment of the globus pallidus (GPi) and substantia nigra pars reticulata (SNr) were obviously lower than the control groups. However, hGAD65 gene transfer did not effectively protect surviving dopaminergic neurons in the SNc and VTA. This study suggests that subthalamic hGAD65 gene therapy and combined with TH gene therapy can alleviate symptoms of the PD model rats, independent of the protection the DA neurons from death.

Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson's disease

2014 ◽  
Vol 65 ◽  
pp. 35-42 ◽  
Author(s):  
Julia Tereshchenko ◽  
Andrea Maddalena ◽  
Mathias Bähr ◽  
Sebastian Kügler
Keyword(s):  
Parkinson’S Disease ◽  
Gene Therapy ◽  
Parkinson's Disease ◽  
Motor Function ◽  
Rat Model ◽  
Gdnf Gene

scholarly journals Delayed Dominant-Negative TNF Gene Therapy Halts Progressive Loss of Nigral Dopaminergic Neurons in a Rat Model of Parkinson's Disease

2011 ◽  
Vol 19 (1) ◽  
pp. 46-52 ◽  
Author(s):  
Ashley S Harms ◽  
Christopher J Barnum ◽  
Kelly A Ruhn ◽  
Steve Varghese ◽  
Isaac Treviño ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Gene Therapy ◽  
Parkinson's Disease ◽  
Rat Model ◽  
Dopaminergic Neurons ◽  
Dominant Negative ◽  
Progressive Loss ◽  
Tnf Gene
Sign in / Sign up

Export Citation Format

Share Document